A 40-week randomized trial found that semaglutide added to reduced insulin glargine improved HbA1c and weight compared with titrated insulin alone, but gastrointestinal side effects were more common.
A pediatric review found GLP-1 medicines may help selected children and teens with obesity or type 2 diabetes, but long-term safety data remain limited.
An ENDO 2026 real-world study linked semaglutide with fewer bone fractures than several other weight-loss medicines in adults with type 2 diabetes. The finding is interesting, but it does not prove semaglutide prevents fractures.
A new FLOW analysis reports that semaglutide kidney and all-cause death benefits were consistent across cardiovascular-risk groups in adults with type 2 diabetes and chronic kidney disease.
New Research Confirms GLP-1 Medications Protect the Heart, Not Just Blood Sugar: cardiovascular outcome trial evidence, who benefits most, and how this drug.
